Presentation is loading. Please wait.

Presentation is loading. Please wait.

HIV and Aging: The Spectrum of Disease Changes

Published byOliver Eriksen Modified over 5 years ago

Similar presentations

Presentation on theme: "HIV and Aging: The Spectrum of Disease Changes"— Presentation transcript:

1 HIV and Aging: The Spectrum of Disease Changes
Amy C. Justice, MD, PhD Associate Professor of Medicine and Public Health Yale University International AIDS Society–USA

2 Disclosure Information
Dr Justice had no relevant financial affiliations to disclose. (02/24/09) International AIDS Society–USA

3 Are the increasing number of “non-AIDS” events primarily due to:
The price of success: People are living long enough on HAART to die of something else HIV disease progression Chronic inflammation ARV toxicity No primary driver

4 “By 2015, an estimated 50% of people living with HIV/AIDS [in the US] will be over 50 years of age.”
Aging Hearing: HIV over fifty, exploring the new threat. Senate Committee on Aging. Washington, DC

5 People with HIV are Living Longer
Denmark: Ann Intern Med 2007:146: New York IDU: CID 2005:41: Barcelona: HIV Medicine 2007;8:251-8

6 Older People are Becoming Infected: New US AIDS Cases
Number of New Cases per Year Distribution of New Cases 80000 25% 70000 20% 60000 50000 15% 40000 10% 30000 20000 Since 1993, the number of new AIDS cases has dramatically decreased in younger patients but has remained relatively constnat in older patients. As a consequence, the proporiton of cases in older patients has incresed, now accounting for over 20% of all new cases of AIDS in the US as of 2007. 1981 – 1999 data from CDC Wonder data; cases diagnosed in the year shown. & cumulative data from 200 – 2001 data from All surveillance reports available at 5% 10000 0% 1981 1985 1989 1993 1997 2001 2005 1981 1985 1989 1993 1997 2001 2005 Age <50 Age ≥50 Age  50 Age >=50

7 Older People Do Not Do As Well: Survival/AIDS by Seroconversion Age
Median time to AIDS Age 15 – 24: 11 years Age  65: 5 years The mortality rate per 1000 person-years increased by a factor of 1·47 (1·41­1·53) for each 10-year increase in age at seroconversion, whereas for AIDS excluding Kaposi's sarcoma the corresponding factor was 1·32 (1·26­1·38). Data from 38 separate cohorts of seroconverters. Lancet 2000; 355:1131

8 Age-Related CD4 Response
Viard, Data from EuroSIDA, JID 2001; 183:1292

9 Virologic Response to HIV Treatment
Most studies suggest that older patients have as good or better virologic response to HAART Excellent response to VL <50 Possible relationship to better adherence

10 Life Expectancy is Not “Normal”
At HAART Initiation CD4 Cell Count (mm3) <100 >200 A 20 yr old will live to 52 62 70 A 35 yr old will live to 65 72 Years lost/1000 PY 461 265 138 Adapted from ART-CC, Lancet 2008;372: by adding additional expected survival to age at treatment initiation.

11 “Non AIDS” Deaths More Common
Source Non AIDS Leading Causes Ref NY Death Certificates 26% Alcohol/drug abuse (31%), CVD (24%), Cancer (21%) Ann Intern Med 2006;145: Barcelona Death 60% Liver ( 23%), Infection (14%), Cancer (11%), CVD (6%) HIV Med 2007:8;251-8 HOPS Chart Rev. 63% Liver (18%), CVD (18%), Pulmonary (16%), Renal (12%), GI (11%), Infection (10%) Cancer (8%) J Acquir Immune Defic Syndr 2006;43:27-34 Cascade Liver (20%), Infections (24%), Unintentional (33%), Cancer (10%), CVD (9%) AIDS 2006; 20;741-9

12 Frailty vs Age and Duration of HIV Infection
Yrs of HIV infection Desquilbet L. J Gerontol Series A ; 62:1279.

13 Spectrum Change More people over 50 with HIV
More people over 50 seroconverting Higher prevalence of Non-AIDS disease -Comorbidity -Toxicity More people dying of Non-AIDS conditions

14 Is This The Price of Success?
No surprise that older people have an increased risk of mortality. Are younger people simply living long enough to experience unrelated conditions and to die from them? Or, is something else happening?

15 Adapted from Goulet et al, AIDS 2005 (Suppl 3); S99-S105

16 Strategies for Management of ARV Therapy (SMART)
RCT of interrupted ARV treatment based on immune reconstitution to minimize toxicity As expected, found that AIDS events (and deaths) were decreased among those on continuous ARVs Also found that non-AIDS events were higher in those randomized to interrupted therapy Liver, renal and cardiovascular events HR 1.7, 95% CI: Strategies for Management of Antiretrivoral Therapy NEJM 2006;355:

17 More AIDS and “Non-AIDS” Events Among Rx. Sparing Arm (SMART)
Intensive Total All Cause Death 55 30 85 Serious OI 13 2 15 Nonserious OI 63 18 81 Major CAD, Renal, or Liver Disease 65 39 104 Strategies for Management of Antiretrivoral Therapy NEJM 2006;355:

18 But, how do we determine which are and which aren’t?
SMART concluded that some “non-AIDS” events may be caused by HIV But, how do we determine which are and which aren’t?

19 What Does It Matter? If a condition is more likely or progresses rapidly due to HIV infection Early HAART may be indicated for those with or at high risk for the condition If a condition is more likely or progresses rapidly due to a specific ARV or class Then other ARVs or classes might be selected If a condition is independent of HIV or its treatment Then conventional approaches to management can be adapted to those with HIV

20 Associations Offering Clues to Etiology
Caveat: these studies are based upon observational data. In such analyses, causality can never be proven, only increasingly strong associations documented.

21 Associated with HIV Infection
Increased among those with HIV infection (vs. without) Increased at lower CD4 count or higher HIV RNA Should improve with ARV therapy Warning: make sure uninfected controls are demographically and behaviorally similar to those with HIV

22 Association with Antiretroviral Therapy (ARV)
Increased among particular drugs or drug classes Should increase with increased drug exposure Warning: -Difficult to differentiate from HIV except when in opposite directions (e.g. hyperlipidemia) -Consider bias by indication -Consider “return to health” (e.g. weight gain)

23 Comorbidity Associated with Warning: Race, gender, age
Socioeconomic status Tobacco, alcohol, drugs Other lifestyle behaviors (obesity, inactivity) Warning: -May confound association with HIV or ARVs -Possibility of synergy—need to study populations at risk

24 Real Life Example: Liver Disease
52 y/o past IDU with HIV/HCV Same regimen of HAART for 8 years with good viral suppression Dies with a CD4 cell count of 250 and hepatocellular carcinoma

25 One Condition, Multiple Etiologies
Substance use Drugs, ALCOHOL Cause of nonadherence Viral hepatitis Chronic Hepatitis C and B Medication toxicity Antiretrovirals (nevaripine, D drugs) Non-HIV medications HIV infection Chronic inflammation Immune compromise with deregulation Liver Disease

26 Hepatic Mortality Among HIV+
Risk Factors for Hepatic Mortality Mortality vs CD4 Count Relative Rate Risk per 2x  CD4 1.23 Risk per 1.0 log VL 1.27 Risk per 5 yr  age 1.32 IDU 2.01 Active HBV infection 3.73 HCV infection 6.66 0.01 0.1 1 10 100 <50 50-99 500 Latest CD4 Count Deaths/100 patient years AIDS mortality Hepatic mortality Adjusted Relative Rate is shown D:A:D study: Weber et al, Arch Intern Med 2006

27 Alcohol & Liver Disease
Percent FIB-4 >3.25 Lim et al, under review, Hepatology

28 Characteristic IRR 95% CI IRR 95% CI
VC Hepatocellular Carcinoma Standardized IRRs Comparing HIV Infected Patients With HIV Negative Controls (n=42,037) Model Model 2 Characteristic IRR 95% CI IRR 95% CI HIV to to 1.6 HCV — — to 24.3 Alcohol ab/depend — — to 3.4 Age to to 1.1 Race Black to to 2.7 Hispanic to to 8.8 Unknown/other to to 4.0 McGinnis et al. Hepatocellular Carcinoma and Non-Hodgkin’s Lymphoma: The Role of HIV, Hepatitis C Infection, and Alcohol Abuse J Clin Oncol :

29 2 More Real Life Examples

30 Intracranial Hemorrhage
Black box warning for Tipranavir (TPV) Rate on TPV exceeded uninfected rates VA and California Medicaid data showed: Similar rate among those with HIV prior to TPV Risk of ICH for HIV infected: 2.5, 95% CI Risk of ICH after AIDS: 2.1, 95% CI VA and California Medicaid rates differed Need to treat patients with TPV for a year before seeing a single excess ICH events AC Justice, DS Zingmond, KS Gordon, et al. CID :

31 Bone Mineral Density in HIV+/-
Brown TT & Qaqish RB. AIDS ; 20: Overton T et al. CROI Abstract 836

32 Osteoporosis/Osteopenia
Osteoporosis requires a fragility fracture, osteopenia is a risk factor for fracture Increased osteopenia (BMD of femoral neck and lumbar spine: Arnsten et al AIDS 21: ) has been demonstrated One age adjusted study (Triant et al J Clin Endo and Metabolism : ) documented increased fragility fractures among men and women with a RR of ~1.3-2

33 Snapshot of “NonAIDS” Associations

34 Non AIDS Conditions Increased Comparing HIV+/-
Condition (confounder) Evidence HAART Anemia (zidovudine) Strong Improves Venous Thrombosis Moderate Unknown Intracranial Hemorrhage CAD (cocaine use, HCV) Increasing Conflicting Obstructive Lung Disease (tobacco) Early Non HIVAN Renal Disease (hypertension, diabetes) Osteoporosis (tob., alc., wasting) Chronic viral hepatitis (alcohol)

35 Non-AIDS Cancers Increased Comparing HIV+/-
Cancer (confounder) Evidence IRR Anal Cancer (MSM) Strong 10-30 Hodgkin’s Lymphoma ~5 Lung Cancer (smoking) Moderate 1-3 Melanoma (sun exposure)

36 Non-AIDS Conditions Associated with Treatment (Comparing HAART+/-)
Evidence Time on Drug Obesity HAART Strong Unknown Hyperlipidemia Hypertension Early (PIs) Diabetes/ Glu Intolerance Strong (PIs) Renal Disease Tenofovir Increases Liver Disease Nevaripine, D Drugs CAD PIs, Abacavir?

37 Implications for HIV Care
HIV infection increases risk and progression of common infectious and noninfectious conditions Screening/treatment guidelines for non-AIDS condition need to be tailored for those with HIV Some non-AIDS conditions may justify earlier or more aggressive ARV treatment Selected ARV treatments likely cause/exacerbate some non-AIDS conditions, but effects are often less pronounced than those of HIV itself We need a more integrated index of relevant biomarkers with which to follow HIV as a complex chronic disease

38 Implications for Research: Cause of Death
Until we know what is truly driving “NonAIDS” mortality we should not be so quick to dismiss it

39 Implications for Research: We Need A Clinical Index for Chronic HIV
AIDS-defining conditions are rare and have variable associations with mortality CD4 count and HIV-RNA do not capture the full effect of ARV treatment Mortality events are too delayed to be primary outcome for most RCTs We need an index that integrates and prioritizes these events with respect to overall risk of mortality

40 West Haven/Yale VACS Project Team

41 National VACS Project Team

42 Veterans Aging Cohort Study
PI and Co-PI: AC Justice, DA Fiellin Scientific Officer (NIAAA): K Bryant Participating VA Medical Centers: Atlanta (D. Rimland, C Jones-Taylor), Baltimore (KA Oursler, R Titanji), Bronx (S Brown, S Garrison), Houston (M Rodriguez-Barradas, N Masozera), Los Angeles (M Goetz, D Leaf), Manhattan-Brooklyn (M Simberkoff, D Blumenthal, J Leung), Pittsburgh (A Butt, E Hoffman), and Washington DC (C Gibert, R Peck) Core Faculty: K Mattocks (Deputy Director), S Braithwaite, C Brandt, K Bryant, R Cook, J Conigliaro, K Crothers, J Chang, S Crystal, N Day, J Erdos, M Freiberg, M Kozal, M Gaziano, M Gerschenson, B Good, A Gordon, J Goulet, M Hernan, K Kraemer, J Lim, S Maisto, P Miller, L Mole, P O’Connor, R Papas, H Paek, J Robins, C Rinaldo, M Roberts, J Samet, B Tierney, J Whittle Staff: D Cohen, A Consorte, K Gordon, F Kidwai, F Levin, K McGinnis, M Rambo, J Rogers, M Skanderson, F Whitsett Major Collaborators: Immunology Case Registry, Pharmacy Benefits Management, Framingham Heart Study, Women’s Interagency HIV Study, Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Health Economics Research Center (HERC), Center for Health Equity Research and Promotion (CHERP), ART-CC, NA-ACCORD Funded by: National Institute on Alcohol Abuse and Alcoholism (2U10 AA 13566); National Institute on Aging (K23 G00826); Robert Wood Johnson Generalist Faculty Scholar Award; an Inter-Agency Agreement between National Institute on Aging, National Institute of Mental Health, and the Veterans Health Administration; the VHA Office of Research and Development; and, VHA Public Health Strategic Health Care Group.

43 Stay tuned.

44 Are the increasing number of “non-AIDS” events primarily due to:
The price of success: People are living long enough on HAART to die of something else HIV disease progression Chronic inflammation ARV toxicity No primary driver

Download ppt "HIV and Aging: The Spectrum of Disease Changes"

Similar presentations

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,

HIV Disease in Older Patients Donna M. Gallagher, ANP The International AIDS Society–USA DM Gallagher, ANP. Presented at IAS–USA/RWCA Clinical Conference,
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.

Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,

NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.

Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.

HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.

Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.

Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.

Slide 1 of 11 From DA Wohl, MD, at New York, NY: May 03, 2012, IAS-USA. IAS–USA David Alain Wohl, MD Associate Professor of Medicine The University of.
Should We be Measuring Mortality in HIV Clinical Programs? September 13 th, 2012 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program;

Should We be Measuring Mortality in HIV Clinical Programs? September 13 th, 2012 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program;
Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.

Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.

Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,

Generously supported by the Robert Wood Johnson Foundation Clinical Scholars Program, Department of Veteran Affairs, and National Institutes of Health,
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.

David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Introductory talk D Costagliola.

Introductory talk D Costagliola.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.

Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Changing Epidemiology of Opportunistic Infections in the HAART Era International AIDS Society 2012 Henry Masur MD Chief, Critical Care Medicine Department.

Changing Epidemiology of Opportunistic Infections in the HAART Era International AIDS Society 2012 Henry Masur MD Chief, Critical Care Medicine Department.
Veterans Aging Cohort Study (VACS)

Veterans Aging Cohort Study (VACS)
Evaluation of Intracranial Hemorrhage in 49,610 HIV-Infected Veterans and California Medicaid Recipients Shawn L. Fultz 1, David Zingmond 2, Kirsha S.

Evaluation of Intracranial Hemorrhage in 49,610 HIV-Infected Veterans and California Medicaid Recipients Shawn L. Fultz 1, David Zingmond 2, Kirsha S.

Similar presentations

Ads by Google